Onsdag 28 Oktober | 22:13:25 Europe / Stockholm

All ägardata du vill ha finns i Holdings!

Mendus Q2 2025 - Nearing phase III-readiness

2025-08-22 10:42:00

Redeye provides its comment on Mendus’ Q2 2025 report. Mendus is approaching phase III-readiness with vididencel in AML in H2 2025e, and we suspect business development will play a significant role in securing late-stage financing. We update our estimates and valuation.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/